The Stoyanova lab has discovered that Notch1 is overexpressed in high grade prostate cancer compared to low grade prostate cancer or benign prostate, and that Notch1 synergizes with several common prostate cancer alterations to drive aggressive disease. Dr. Rice determined that Notch1 is a therapeutically relevant target in prostate cancer and is exploring novel inhibition strategies in prostate cancer.
Congratulations Dr. Rice!